Mauna Kea announced plans to commence a first in human clinical trial in partnership with Johnson & Johnson's Lung Cancer Iniave to evaluate the feasibility and safety of J&J’s Monarch catheter-based robocs plaorm in combinaon with Cellvizio for the diagnosis of peripheral lung nodules. Mauna Kea has remained ght lipped with regards to the company's partnership with J&J since a strategic equity investment of €7.5m in December 2019. In our view, the iniaon of the
01 Jul 2020
IP/roboc surgery play gathering momentum
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
IP/roboc surgery play gathering momentum
Mauna Kea Technologies SA Class O (0P5I:LON) | 0 0 0.2% | Mkt Cap: 75.0m
- Published:
01 Jul 2020 - Author:
-
Pages:
17
Mauna Kea announced plans to commence a first in human clinical trial in partnership with Johnson & Johnson's Lung Cancer Iniave to evaluate the feasibility and safety of J&J’s Monarch catheter-based robocs plaorm in combinaon with Cellvizio for the diagnosis of peripheral lung nodules. Mauna Kea has remained ght lipped with regards to the company's partnership with J&J since a strategic equity investment of €7.5m in December 2019. In our view, the iniaon of the